Carfilzomib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Romiplostim
Colony-Stimulating Factor · Antihaemorrhagic
Also known as NPLATE
Colony-Stimulating FactorAntihaemorrhagic
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- CarfilzomibSevereDatabaseDDInter
Mechanism
Romiplostim contains four copies of a small peptide that binds with high affinity to the thrombopoietin receptor, grafted onto an immunoglobulin scaffold. It binds to and activates the thrombopoietin (TPO) receptor, thereby increasing platelet production.
Indications
Chronic immune (idiopathic) thrombocytopenic purpura in patients refractory to other treatments (such as corticosteroids or immunoglobulins)immune thrombocytopenia (ITP) with insufficient response to corticosteroids, immune globulin, or splenectomy
Dosing
- Adult
- Administered weekly by subcutaneous injection, starting with a dose of 1 μg/kg, titrated until platelet count increases above 50,000/μL.
- Max dose
- 10 μg/kg
Side effects
Serious
- Thromboembolic disease (if platelet count rises to very high levels)
- thrombosis
- marrow fibrosis
- rebound thrombocytopenia
Drug interactions
Related guidelines
Sjögren's syndrome
EULAR · Rheumatology · 2025
Postpartum haemorrhage
FOGSI · Obstetrics & Gynaecology · 2024
Preventive care in inflammatory bowel disease
ACG · Gastroenterology · 2025
Generalised anxiety disorder and panic disorder
NICE · Psychiatry · 2020
Hepatitis C — chronic infection
EASL · Gastroenterology · 2020
Other Colony-Stimulating Factor drugs
Ask House about Romiplostim
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team